TABLE 1.
Clinical trials on NAMPT inhibitors (updated to January 2022).
| Drug | Phase | Conditions | Status | Nut identifier | Outcome measures | Display of results on ClinicalTrials.gov |
|---|---|---|---|---|---|---|
| GMX1777 | Ⅰ | Solid Tumors and Lymphomas | Withdrawn | NCT00457574 | No Results Posted | |
| GMX1777+, Temozolomide | ⅠⅡ | Metastatic Melanoma | Terminated | NCT00724841 | Primary Outcome Measures: Determine the recommended Phase II dose of GMX1777 in combination with temozolomide [ Time Frame: 2 years ] Learn more about the side effects of taking GMX1777 in combination with temozolomide [ Time Frame: Within the first 4 weeks ] Determine the disease response to treatment with GMX1777 in combination with temozolomide [ Time Frame: Within the first 8 weeks ] | No Results Posted |
| Secondary Outcome Measures: Learn more about how the body processes GMX1777 [ Time Frame: Within the fisrt 30 days ] | ||||||
| CHS828 | Ⅰ | Unspecified Adult Solid Tumor, Protocol Specific | Withdrawn | NCT00003979 | No Results Posted | |
| APO866 | Ⅰ Ⅱ | B-cell Chronic Lymphocytic Leukemia | Completed | NCT00435084 | Primary Outcome Measures: Safety and tolerability of APO866 in patients with refractory B-CLL not amenable to allogeneic HSCT [ Time Frame: 1 month] | |
| Secondary Outcome Measures: To determine the effect on the number of circulating leukemic after treatment as compared to baseline [Time Frame: 1 month]. To determine the effect on the number of CD38+ after treatment as compared to baseline [Time Frame: 1 month] | ||||||
| Correlative analysis on in vivo and in vitro sensitivity of leukemic cells, CD38 expression of leukemic cells and clinical outcome, immunophenotype and clinical outcome [Time Frame: 1 month] | ||||||
| APO866 | Ⅱ | Melanoma | Completed | NCT00432107 | Primary Outcome Measures: To determine the tumor response rate (according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria) as the proportion of eligible patients with stage IV cutaneous melanoma or stage III not amenable to surgery. [Time Frame: Week 16] | No Results Posted |
| Secondary Outcome Measures: Safety and tolerability [Time Frame: Week 16 and 12 months follow-up] | ||||||
| Time to response [Time Frame: Week 16] | ||||||
| Duration of response [Time Frame: Week 16] | ||||||
| Progression free survival [Time Frame: 12 months] | ||||||
| Overall survival [Time Frame: 12 months] | ||||||
| Evolution of serum VEGF and interleukin-8 (IL-8) during treatment [Time Frame: Week 16] | ||||||
| APO866 | Ⅱ | Cutaneous T-cell Lymphoma | Completed | NCT00431912 | Primary Outcome Measures: The proportion of eligible patients with refractory or relapsed CTCL whom have a complete response or partial response on cutaneous lesions (Tumor Burden Index) and extra-cutaneous disease. [Time Frame: Week 16] | No Results Posted |
| Secondary Outcome Measures: Safety and tolerability, time to response, duration of overall response, duration of stable disease and time to treatment failure. [Time Frame: Week 16] | ||||||
| KPT-9274 | Ⅰ | Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory | Recruiting | NCT04914845 | No Results Posted | |
| KPT-9274 | Ⅰ | Solid Tumors NHL | Terminated | NCT02702492 | Primary Outcome Measures: Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid) [Time Frame: Approximately 4 weeks] | No Results Posted |
| KPT-9274&Niacin | Parts A and B: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1 | |||||
| ER | Maximum tolerated dose (MTD) for KPT-9274 co-administered with nivolumab [ Time Frame: Approximately 4 weeks] | |||||
| KPT-9274 + Nivolumab | Part C: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1 | |||||
| ATG-019 | Ⅰ | Solid Tumor | Recruiting | NCT04281420 | No Results Posted | |
| ATG-019 + Niacin ER | Non-Hodgkin’s Lymphoma | |||||
| OT-82 Dose Escalation | Ⅰ | Lymphoma | Recruiting | NCT03921879 | No Results Posted | |
| OT-82 Dose Expansion | Lymphoma, Non-Hodgkin | |||||
| Lymphoma, B-Cell (and 4 more) |